You can now read 10 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe

Business

MASS. MOVERS

Drug delays cancer’s spread, trials show

Woburn-based ArQule Inc. rallied 12 percent, the most since July 2010. ArQule, a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics, reported that its tivantinib product delayed the progression of cancer in a phase two study of 107 patients. All had liver cancer and had been treated previously. Tivantinib (also known as ARQ 197) is designed to block the activity of a molecule known as c-Met that plays multiple roles in cancer. It is ArQule’s lead product.

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week